Japan Study Equates Bayer's Xarelto With Warfarin Bleeding Risk
This article was originally published in PharmAsia News
Executive Summary
A Japanese study comparing warfarin with Bayer AG's Xarelto (rivaroxaban) for treating patients with arrhythmia found Bayer's drug did not increase the risk of bleeding